全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
药学学报  2013 

番荔枝酰胺衍生物flz对lps联合mptp诱发小鼠慢性帕金森病的治疗作用

, PP. 1557-1562

Keywords: flz,lps,mptp,帕金森病

Full-Text   Cite this paper   Add to My Lib

Abstract:

利用细菌内毒素脂多糖(lps)联合神经毒素mptp诱发的慢性小鼠帕金森病(pd)模型,考察番荔枝酰胺衍生物flz片剂对pd的治疗作用。c57/bl小鼠腹腔注射lps(5mgskg-1)一次,1周后,小鼠皮下注射mptp(25mgskg-1),每天1次,共注射2天。8周后,flz(25、50及75mgskg-1)及阳性对照药l-dopa治疗性给药,每天1次,共给药2个月。以爬杆法及足迹法不同时间评价pd小鼠的行为学能力,高效液相色谱法检测纹状体多巴胺含量,免疫组化法分析黑质纹状体酪氨酸羟化酶(th)阳性细胞数。结果显示,lps与mptp合用能成功诱发小鼠pd样病理改变,在造模后第8周模型组动物爬杆行为学评分与正常对照组相比有显著性降低,在步伐测定实验中出现明显的步伐紊乱和步伐长度减小。flz(25、50及75mgskg-1)治疗性给药2个月,能显著改善pd小鼠的行为学障碍,表现在增加爬杆行为学评分,改善动物的步伐紊乱及步伐长度;同时,提高小鼠黑质th阳性神经元的数量,增加纹状体内多巴胺含量。结果表明,flz片剂对lps联合mptp诱发的慢性炎症性pd小鼠有良好的治疗作用,目前该药已申报临床试验,有望成为新型抗pd药物。

References

[1]  russol,bubaccol,greggioe.exosomes-associatedneurodegenerationandprogressionofparkinson'sdisease[j].amjneurodegenerdis,2012,1:217-225.
[2]  johnstonth,brotchiejm.drugsindevelopmentforparkinson'sdisease:anupdate[j].curropininvestigdrugs,2006,7:25-32.
[3]  baoxq,kongxc,qianc,etal.flzprotectsdopaminergicneuronthroughactivatingproteinkinaseb/mammaliantargetofrapamycinpathwayandinhibitingrtp801expressioninparkinson'sdiseasemodels[j].neuroscience,2012,202:396-404.
[4]  fangf,wangql,liugt.flz,syntheticsquamosamidecyclicderivative,attenuatesmemorydeficitandpathologicalchangesinmicewithexperimentallyinducedaging[j].naunynschmiedebergsarchpharmacol,2012,385:579-585.
[5]  nolanym,sullivanam,toulousea.parkinson'sdiseaseinthenuclearageofneuroinflammation[j].trendsmolmed,2013,19:187-196.
[6]  pradhans,andreassonk.commentary:progressiveinflammationasacontributingfactortoearlydevelopmentofparkinson'sdisease[j].expneurol,2013,241:148-155.
[7]  bylersl,boehmgw,karpjd,etal.systemiclipopolysac­charideplusmptpasamodelofdopaminelossandgaitinstabilityinc57bl/6jmice[j].behavbrainres,2009,198:434-439.
[8]  wersingerc,sidhua.aninflammatorypathomechanismforparkinson'sdisease?[j].currmedchem,2006,13:591-602.
[9]  simondk,standaertdg.neuroprotectivetherapies[j].medclinnortham,1999,83:509-523.
[10]  marsdencd,olanowcw.thecauseofparkinson'sdiseasearebeingunraveledandrationalneuroprotectivetherapyisclosetoreality[j].annneurol,1998,44:s189-196.
[11]  armenteromt,pinnaa,ferres,etal.past,presentandfutureofa(2a)adenosinereceptorantagonistsinthetherapyofparkinson'sdisease[j].pharmacolther,2011,132:280-299.
[12]  panxd,chenxc.advancesinthestudyofimmuno­pharmacologicaleffectsandmechanismsofextractsoftripterygiumwilfordiihook.f.inneuroimmunologicdisorders[j].actapharmsin(药学学报),2008,43:1179-1185.
[13]  zhangd,zhangjj,liugt.thenovelsquamosamidederivativeflzprotectsagainst6-hydroxydopamine-inducedapoptosisthroughinhibitionofrelatedsignaltransductioninsh-sy5ycells[j].eurjpharmacol,2007,561:1-6.
[14]  zhangd,zhangjj,liugt.thenovelsquamosamidederivative(compoundflz)attenuated1-methyl-4-phenyl-pyridiniumion(mpp+)-inducedapoptosisandalternationsofrelatedsignaltransductioninsh-sy5ycells[j].neuro­pharmacology,2007,52:423-429.
[15]  gandhis,woodnw.molecularpathogenesisofparkinson'sdisease[j].hummolgenet,2005,14:2749-2755.
[16]  baramo,amitt,youdimmb.contrastingneuroprotectiveandneurotoxicactionsofrespectivemetabolitesofanti-parkinsondrugsrasagilineandselegiline[j].neuroscilett,2004,355:169-172.
[17]  fanl,jiangxg.developmentofgenetherapyinmajorbraindiseases[j].actapharmsin(药学学报),2010,45:1095-1102.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133